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Identity 
Other names: ING1L; ING1Lp; p32; p33ING2 




The two isoforms share exon 2 but have different exon 
1. The exon 1a of ING2a encodes 58 amino acids. Exon 
1b of ING2b encodes 18 amino acids. There is no 
significant homology between the N-terminal part of 
ING2b and the N-terminal regions of ING1 isoforms 
(Unoki et al., 2008). 
Transcription 
The promoter region of ING2a possesses two p53 
binding sites in contrast to the promoter of ING2b. 
Binding of p53 to these sites suppresses the ING2a 
expression. The promoter region of ING2b harbors a 
HSF1 and HSF2 binding site, a c-Rel, a SP1 and five 
MZF1 binding sites (Unoki et al., 2008). 
Protein 
Description 
p33ING2a: 280 amino acids; 33kDa protein; harbor, 
listed from the N-terminal to the C-terminal region, a 
leucine-zipper-like-region (LZL), a novel conserved 
region (NCR), a nuclear localization signal (NLS), a 
plant homeo domain (PHD) finger motif and a poly 
basic region (PBR); p28ING2b: 240 aa; 28 kDa 
protein; lacks leucine-zipper-like-domain (LZL) is 
distinct to the N-termi-nal part to ING2a (Unoki et al., 
2008). 
Expression 
ING2 is widely expressed in normal tissues (Shimada 
et al., 1998). 
Localisation 
ING2 is predominantly localized in the nucleus to 
chromatin and the nuclear matrix (Gozani et al., 2003). 
Through reduced levels of phosphoinositide PtdIns5P, 
ING2 might be released from chromatin and 
translocates partially to the cytoplasm (Gozani et al., 
2003). 
 
Gene structure of ING2a and ING2b (modified according to Unoki et al., 2008). 
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Function 
The tumor suppressor protein ING2 has been described 
to regulate cell cycle, cellular senescence and gene 
regulation including chromatin level. In response to 
DNA damage ING2 enhances the acetylation of p53, 
which negatively regulates cell proliferation 
(Nagashima et al., 2001). In addition the level of ING2 
expression directly regulates the onset of replicative 
senescence through the induc-tion of p300-dependent 
acetylation of p53 (Pedeux et al., 2005). ING2 also 
induces the global histone H4 acetylation and 
chromatin relaxation and thereby enhances the 
nucleotide excision repair (Wang et al., 2006). 
Furthermore, ING2 is also a part of two related 
mSin3/HDAC1/HDAC2 corep-ressor complexes 
(Doyon et al., 2006). Further, chromatin association of 
ING2 is linked to ING2 ability to bind to trimethylated 
K4 of histone 3 (H3K4me3) via its plant homeodomain 
(PHD) region (Shi et al., 2006). p33ING2 is also 
associated with histone methyltranferase (HMT-) 
activity in vitro and in vivo, methylating specifi-cally 
histone H3 and histone H1 (Goeman et al., 2008). In 
addition, ING2, as a transcriptional rep-ressor, directly 
interacts with the corepressor Alien and enhances the 
Alien-mediated gene silencing (Fegers et al., 2007). 
Furthermore, ING2 interacts with the Smad-interaction 
transcriptional modulator SnoN mediating TGF-beta-
induced Smad-depen-dent transcription and cellular 
responses (Sarker et al., 2008). The activity of ING2, as 
a nuclear phosphatidylinositol receptor can be 
modulated by phosphoinositides (Gozani et al., 2003). 
Homology 
The PHD-finger motif is highly-conserved among all 
ING genes. There are five human ING genes (ING1, 
ING2, ING3, ING4, ING5) which encode multiple 
isoforms via splicing. So far known ING2 gene 




So far natural occurring point mutations of ING2 in 
association with cancer were not yet described. 
However, loss of heterozygosity (LOH) and aberrant 




ING2 expression level in human colon tumors is 
significantly higher than in normal colon tissue. In 
conclusion, ING2 might be involved in colon cancers 
(Shimada et al., 1998). 
 
Hepatocellular carcinoma (HCC) 
Oncogenesis 
ING2 transcription and post-transcription level is 
downregulated in the majority of HCC tumors 
compared with non-tumors liver tissue. Further-rmore, 
ING2 expression level is reduced in 44 of 84 (52.4%) 
HCC cases and the ING2 expression level correlated 
with tumor size, histopathologic classifi-cation and 
serum AFP (Zhang et al., 2008). It is also shown that 
HCC patients with reduced ING2 expression have a 
significantly increased risk exhibiting a shorter survival 
time. In conclusion, ING2 may be involved in the 
progression of HCC (Zhang et al., 2008). 
Head and neck squamous cell 
carcinoma (HNSCC) 
Oncogenesis 
There is a loss of heterozygosity (LOH) in the region 
4q32 in the long arm of the chromosome 4 in 20% of 
the cases (Borkovsky et. al., 2008). This region 
includes ING2 and SAP30 genes that are parts of the 
two related mSin3/ HDAC1/2 corepres-sor complexes. 
LOH on region 4q35.1 was detected in 30 (54.6%) out 
of 55 informative cases (Borkovsky et. al., 2008). High 
LOH frequency is associated with advanced tumor 




Although, there are no ING2 mutations identified in 30 
human lung cancer cell lines and 31 primary lung 
cancer tumors. The ING2 mRNA expression is reduced 
in 6 out of 7 lung cancer cell lines (Okano et al., 2006). 
Cutaneous melanomas 
Oncogenesis 
The nuclear expression level of ING2 is significantly 
reduced in human melanomas compared to dysplastic 
nevi. It is suggested that reduced ING2 expression may 
be involved in the initiation of melanoma (Lu et al., 
2006; Ythier et al., 2008). 
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